



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 66892

Title: New approaches for patients with advanced radioiodine-refractory thyroid cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03468910

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor, Surgeon

Reviewer's Country/Territory: Italy

Author's Country/Territory: Argentina

Manuscript submission date: 2021-04-08

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2021-07-28 10:46

Reviewer performed review: 2021-08-03 16:41

Review time: 6 Days and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The topic of manuscript falls within the scope of World Journal of Oncology. This manuscript is a review to provide a summary of the current therapeutic strategies in Advanced Radioiodine-Refractory Throid Cancer, including approved target therapies as well as those for off-label use, radioactive iodine resensitization agents and immunotherapy. I think that this manuscript is not novel, but nicely done and it is a good review of the most recent Literature about the current therapeutic strategies in Advanced Radioiodine-Refractory Throid Cancer.